This HTML5 document contains 53 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n8http://linked.opendata.cz/resource/drugbank/drug/DB00083/identifier/pharmgkb/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00083/identifier/kegg-compound/
n15http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n27http://linked.opendata.cz/resource/drugbank/company/
n13http://linked.opendata.cz/resource/mesh/concept/
n21http://linked.opendata.cz/resource/drugbank/dosage/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00083/identifier/kegg-drug/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00083/identifier/drugbank/
n16http://bio2rdf.org/drugbank:
n22http://linked.opendata.cz/resource/drugbank/drug/DB00083/identifier/national-drug-code-directory/
admshttp://www.w3.org/ns/adms#
n25http://www.rxlist.com/cgi/generic/
n23http://linked.opendata.cz/resource/drugbank/patent/
n5http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n6http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n12http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n11http://linked.opendata.cz/resource/drugbank/property/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00083/identifier/genbank/
xsdhhttp://www.w3.org/2001/XMLSchema#
n20http://linked.opendata.cz/resource/drugbank/drug/DB00083/identifier/uniprotkb/
n9http://linked.opendata.cz/resource/drugbank/drug/DB00083/identifier/wikipedia/
n14http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00083
rdf:type
n3:Drug
n3:description
Purified botulinum toxin from Clostridium botulinum, purified from culture via dialysis and acid precipitation.
n3:dosage
n21:271B43D0-363D-11E5-9242-09173F13E4C5 n21:271B43D1-363D-11E5-9242-09173F13E4C5 n21:271B43D2-363D-11E5-9242-09173F13E4C5 n21:271B43CC-363D-11E5-9242-09173F13E4C5 n21:271B43CD-363D-11E5-9242-09173F13E4C5 n21:271B43CE-363D-11E5-9242-09173F13E4C5 n21:271B43CF-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Montecucco C, Molgo J: Botulinal neurotoxins: revival of an old killer. Curr Opin Pharmacol. 2005 Jun;5(3):274-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15907915 # Brin MF, Lew MF, Adler CH, Comella CL, Factor SA, Jankovic J, O'Brien C, Murray JJ, Wallace JD, Willmer-Hulme A, Koller M: Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology. 1999 Oct 22;53(7):1431-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10534247 # Shukla HD, Sharma SK: Clostridium botulinum: a bug with beauty and weapon. Crit Rev Microbiol. 2005;31(1):11-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15839401 # Eisenach JH, Atkinson JL, Fealey RD: Hyperhidrosis: evolving therapies for a well-established phenomenon. Mayo Clin Proc. 2005 May;80(5):657-66. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15887434 # Schurch B, Corcos J: Botulinum toxin injections for paediatric incontinence. Curr Opin Urol. 2005 Jul;15(4):264-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15928517
n3:group
approved investigational
n3:indication
For the treatment of cervical dystonia in adults to decrease the severity of abnormal head position and neck pain associated with cervical dystonia. Also for the treatment of severe primary axillary hyperhidrosis that is inadequately managed with topical agents and for the treatment of strabismus and blepharospasm associated with dystonia, including benign essential blepharospasm or VII nerve disorders in patients 12 years of age and above. Also used cosmetically to temporarily improve the appearance of moderate-to-severe frown lines between the eyebrows (glabellar lines) as well as for the treatment of excessive underarm sweating.
owl:sameAs
n5:DB00083 n16:DB00083
dcterms:title
Botulinum Toxin Type A
adms:identifier
n8:PA164754825 n9:Botox n17:C07946 n18:D00783 n19:X52066 n20:P10845 n22:99207-500-30 n26:DB00083
n3:mechanismOfAction
Botulinum Toxin Type A blocks neuromuscular transmission by binding to acceptor sites on motor or sympathetic nerve terminals, entering the nerve terminals, and inhibiting the release of acetylcholine. This inhibition occurs as the neurotoxin cleaves SNAP-25, a protein integral to the successful docking and release of acetylcholine from vesicles situated within nerve endings.
n3:packager
n27:271B43C3-363D-11E5-9242-09173F13E4C5 n27:271B43C4-363D-11E5-9242-09173F13E4C5
n3:patent
n23:2280565 n23:2310845
n3:synonym
BoNT/A Botulinum neurotoxin type A precursor BTX-A Bontoxilysin A
n3:toxicity
Based on toxicological studies, it has been estimated that the human LD50 by injection is approximately 2800 Units, equivalent to 28 individual vials of BOTOX (Botulinum Toxin Type A) Purified Neurotoxin Complex (100 Units) for a 70 kg adult. When injected intramuscularly, Botulinum Toxin Type A has been shown to be teratogenic or to have embryocidal effects in some animal species.
n14:hasAHFSCode
n15:92-00-00
n12:hasConcept
n13:M0028703
foaf:page
n25:botox.htm
n3:Molecular-Formula
n11:271B43D7-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n11:271B43D6-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n11:271B43D3-363D-11E5-9242-09173F13E4C5
n3:absorption
The chemical complexity of Botulinum Toxin Type A combined with its extreme potency limits the opportunity to study its pharmacokinetic profile in humans. Therefore, no human pharmacokinetic studies have been performed. Botulinum Toxin Type A is injected directly into the target organ, a skeletal muscle. Thus, bioavailability of the intravenous or oral route is not of clinical relevance.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
93384-43-1
n3:category
n3:containedIn
n6:271B43CA-363D-11E5-9242-09173F13E4C5 n6:271B43CB-363D-11E5-9242-09173F13E4C5 n6:271B43C8-363D-11E5-9242-09173F13E4C5 n6:271B43C9-363D-11E5-9242-09173F13E4C5 n6:271B43C6-363D-11E5-9242-09173F13E4C5 n6:271B43C7-363D-11E5-9242-09173F13E4C5 n6:271B43C5-363D-11E5-9242-09173F13E4C5
n3:Hydrophobicity
n11:271B43D4-363D-11E5-9242-09173F13E4C5
n3:Isoelectric-Point
n11:271B43D5-363D-11E5-9242-09173F13E4C5